Summary

Glatiramer acetate (copolymer-1, Copaxone) is a synthetic random copolymer of L-alanine, L-glutamic acid, L-lysine, and L-tyrosine in defined molar ratios. Originally developed to mimic myelin basic protein (MBP), it has become one of the most extensively studied immunomodulatory peptides, with over 900 PubMed-indexed publications. It is a licensed POM in the UK for relapsing-remitting multiple sclerosis.

Overview

Glatiramer acetate is a synthetic polypeptide comprising a defined mixture of L-alanine (6.2 mM), L-glutamic acid (1.5 mM), L-lysine (3.4 mM), and L-tyrosine (0.9 mM) residues, polymerised to an average molecular weight of 4,700–11,000 Da. It was originally synthesised at the Weizmann Institute in Israel by Michael Sela and colleagues in the 1960s, initially to induce experimental autoimmune encephalomyelitis (EAE) — but paradoxically, it suppressed the disease instead.

This serendipitous discovery led to decades of research and eventual licensing as Copaxone for relapsing-remitting multiple sclerosis (RRMS). The compound is one of the longest-studied immunomodulatory peptides in clinical medicine.

For research and educational purposes only. Glatiramer acetate is a licensed POM in the UK.

Mechanism of Action

Glatiramer acetate's mechanism is multifaceted and well-documented in the literature:

  1. T-cell receptor antagonism: Glatiramer acetate binds with high affinity to MHC class II molecules on antigen-presenting cells, competing with myelin-derived antigens (MBP, MOG, PLP) for presentation. This prevents activation of autoreactive Th1 cells.

  2. Th2 polarisation: Binding to MHC-II induces differentiation of naive T cells into Th2-type regulatory T cells rather than pro-inflammatory Th1/Th17 cells. These glatiramer-reactive Th2 cells cross the blood-brain barrier and secrete anti-inflammatory cytokines (IL-4, IL-5, IL-10, TGF-beta) that create a bystander suppressive environment.

  3. CD8+ regulatory T cells: Research by Tennakoon et al. (2015) demonstrated that glatiramer acetate also expands CD8+ regulatory T cells, adding another layer of immune suppression.

  4. Innate immune modulation: Glatiramer acetate alters the phenotype of dendritic cells and monocytes toward an anti-inflammatory (type II) profile.

Research Summary

Evidence Grade: Strong

Glatiramer acetate has robust clinical evidence spanning decades:

Multiple Sclerosis: The pivotal trial by Johnson et al. (1995) demonstrated a 29% reduction in relapse rate in RRMS patients over two years. The CONFIRM trial (2012) confirmed sustained efficacy with both once-daily and three-times-weekly formulations. The GALA study (2013) validated a once-weekly 40 mg formulation.

Long-term safety: The 15-year open-label follow-up by Ford et al. (2010) is one of the longest prospective MS treatment studies, demonstrating sustained safety and tolerability with no cumulative toxicity.

Neuroprotective research: Emerging research investigates whether glatiramer acetate's immunomodulatory effects extend beyond relapse reduction to neuroprotection — potentially reducing axonal loss and promoting remyelination.

Key Studies

  1. Johnson KP et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis. Neurology. 1995;45(7):1268-1276.
  2. Gold R et al. (CONFIRM trial). Neurology. 2012;79(4):335-343.
  3. Khan O et al. (GALA study). Annals of Neurology. 2013;73(6):687-695.
  4. Ford C et al. Long-term outcomes with glatiramer acetate. Journal of the Neurological Sciences. 2010;295(1-2):77-82.

Commonly Discussed Protocols

All information is for research and educational purposes only. Glatiramer acetate is a licensed POM — no protocols for unsupervised use are provided.

In published clinical literature:

  • Subcutaneous injection: 20 mg daily or 40 mg three times weekly (licensed dosing)
  • Research dosing in EAE models: 150–500 micrograms per mouse, subcutaneous, typically administered at disease onset or pre-immunisation
  • In vitro research: 10–100 micrograms per mL for dendritic cell and T-cell co-culture studies

Stacking

No established research protocols combine glatiramer acetate with other peptides. In clinical practice, it has been studied alongside interferon-beta (combination therapy), but this is outside the scope of research-peptide use.

Storage & Reconstitution

  • Storage: Store at 2–8°C (refrigerated). Do not freeze. Pre-filled syringes should be kept in their original packaging to protect from light.
  • Reconstitution: Commercial formulations come pre-filled and ready for subcutaneous injection. For laboratory research, lyophilised glatiramer acetate should be reconstituted in sterile PBS or bacteriostatic water.
  • Stability: Reconstituted research material should be stored at –20°C for long-term storage. Avoid repeated freeze-thaw cycles.

Blood Work

In clinical and research contexts involving glatiramer acetate:

  • Routine blood counts: Recommended at baseline and periodically, though glatiramer acetate has a favourable haematological safety profile
  • Liver function tests: Monitor for hepatic enzyme elevations (rare)
  • Injection site reactions: Localised reactions are the most common adverse effect — monitor skin integrity at injection sites
  • No specific peptide-related blood biomarkers are required beyond standard safety monitoring

UK Legal Status

Glatiramer acetate is a licensed prescription-only medicine (POM) in the UK, regulated by the MHRA. It is available under brand names including Copaxone and generic formulations. It is not a controlled substance under the Misuse of Drugs Act.

Research-grade glatiramer acetate for in vitro or laboratory research may be available from established chemical supply houses with appropriate purity documentation. Any use in humans without a prescription is illegal.

Vetted UK Vendors

As glatiramer acetate is a licensed POM, it is not sold as a research peptide by the vetted vendors listed on Peptide Data. Researchers requiring glatiramer acetate for legitimate laboratory research should source it through established chemical supply houses with HPLC-verified purity documentation.

References

  1. Johnson KP et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology. 1995;45(7):1268-1276. PMID: 7617182.
  2. Gold R et al. Efficacy and safety of glatiramer acetate in RRMS (CONFIRM). Neurology. 2012;79(4):335-343. doi:10.1212/WNL.0b013e31825d03ea.
  3. Khan O et al. Efficacy and safety of once-weekly glatiramer acetate 40 mg (GALA). Ann Neurol. 2013;73(6):687-695. doi:10.1002/ana.23938.
  4. Ford C et al. Long-term outcomes with glatiramer acetate in MS. J Neurol Sci. 2010;295(1-2):77-82.
  5. Tennakoon DK et al. Therapeutic induction of regulatory T cells in EAE by glatiramer acetate. J Immunol. 2015;194(9):4257-4267.

References

  1. Johnson KP et al. Copolymer 1 reduces relapse rate and improves disability in RRMS. Neurology. 1995;45(7):1268-1276. PMID: 7617182.
  2. Gold R et al. Efficacy and safety of glatiramer acetate in RRMS (CONFIRM). Neurology. 2012;79(4):335-343. doi:10.1212/WNL.0b013e31825d03ea.
  3. Khan O et al. Efficacy and safety of once-weekly glatiramer acetate 40 mg (GALA). Ann Neurol. 2013;73(6):687-695. doi:10.1002/ana.23938.
  4. Ford C et al. Long-term outcomes with glatiramer acetate in MS. J Neurol Sci. 2010;295(1-2):77-82.
  5. Tennakoon DK et al. Therapeutic induction of regulatory T cells in EAE by glatiramer acetate. J Immunol. 2015;194(9):4257-4267.